Kumar Srinivasan

VP and Global Head of Business Development and Licensing, BioPharmaceuticals R&D at AstraZeneca Pharmaceuticals

Kumar Srinivasan joined AstraZeneca in April 2012 to head up business development for the newly-constituted AZ Neuroscience group and was promoted to VP & Head of Scientific Partnering & Alliances in March 2013. The SP&A team led by Kumar was instrumental in key collaborations across core therapeutic areas and neuroscience to add significant value to AZ’s early pipeline programs. As of August 2019, Kumar assumed a new role as Vice President and Global Head of Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca. In his most recent external position, Kumar was Chief Business Officer at Probiodrug AG, then a private venture-funded German company developing novel treatments for Alzheimer’s disease and inflammatory diseases. Prior to joining Probiodrug, Kumar was Vice President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre phase 2 opportunities for several therapeutic areas.